Ramucirumab (Synonyms: LY3009806) |
| Katalog-Nr.GC19534 |
Ramucirumab ist ein humaner VEGFR-2-Antagonist zur Behandlung von soliden Tumoren. Ramucirumab ist ein rekombinanter humaner monoklonaler Immunglobulin-G1-AntikÖrper, der an die extrazellulÄre BindungsdomÄne von VEGFR-2 bindet und die Bindung von VEGFR-Liganden verhindert: VEGF-A, VEGF-C und VEGF-D. Ramucirumab ist auch ein Angiogenese-Hemmer.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 947687-13-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Ramucirumab is a fully human monoclonal antibody (IgG1). Ramucirumab is a direct VEGFR2 antagonist, that binds with high affinity to the extracellular domain of VEGFR2 and block the binding of natural VEGFR ligands (VEGF-A, VEGF-C and VEGF-D). These ligands are secreted by solid tumors to promote angiogenesis (formation of new blood vessels from pre-existing ones) and enhance tumor blood supply. Binding of ramucirumab to VEGFR2 leads to inhibition of VEGF-mediated tumor angiogenesis.
Average Rating: 5 (Based on Reviews and 29 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *